June 2015
Volume 56, Issue 7
Free
ARVO Annual Meeting Abstract  |   June 2015
Efficacy of ISTH0036, a Potent and Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-β2) Isoform, in Different Ocular Disease Preclinical Models
Author Affiliations & Notes
  • Michel Janicot
    JMi ONConsulting, Brussels, Belgium
  • Kathy Hasenbach
    Preclinical RnD, Isarna Therapeutics, Munich, Germany
  • Tine Van Bergen
    Laboratory of Ophthalmology, KUL, Leuven, Belgium
  • Lieve K M Moons
    Department of Biology, Zoological Institute, Leuven, Belgium
  • Ingeborg Stalmans
    Laboratory of Ophthalmology, KUL, Leuven, Belgium
  • Katja Wosikowski
    Preclinical RnD, Isarna Therapeutics, Munich, Germany
  • Footnotes
    Commercial Relationships Michel Janicot, None; Kathy Hasenbach, None; Tine Van Bergen, None; Lieve Moons, None; Ingeborg Stalmans, None; Katja Wosikowski, None
  • Footnotes
    Support None
Investigative Ophthalmology & Visual Science June 2015, Vol.56, 1278. doi:https://doi.org/
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Michel Janicot, Kathy Hasenbach, Tine Van Bergen, Lieve K M Moons, Ingeborg Stalmans, Katja Wosikowski; Efficacy of ISTH0036, a Potent and Selective Antisense Oligonucleotide Targeting Transforming Growth Factor beta 2 (TGF-β2) Isoform, in Different Ocular Disease Preclinical Models. Invest. Ophthalmol. Vis. Sci. 2015;56(7 ):1278. doi: https://doi.org/.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose: ISTH0036 is a 14-mer phosphorothioate Locked Nucleic Acid- (LNA) modified antisense oligonucleotide gapmer, targeting TGF-β2 mRNA. It was shown to effectively and potently downregulate target mRNA in a dose-dependent manner in relevant cell-based assays, as well as leading to target engagement in anterior eye segment tissues upon intravitreal administration. The aim of the presented study was to evaluate the therapeutic potential of ISTH0036 in murine models of glaucoma filtration surgery (GFS) and laser-induced choroidal neovascularization (CNV) following intra-ocular administration.

Methods: Either Intracameral or intravitreal injections with ISTH0036, relevant scrambled control oligonucleotide or saline were performed in C75Bl/6 mice on day 0 and day 14 after GFS (trabeculectomy). CNV was induced in mice by placing 3 laser spots using a 532 nm laser. Intravitreal injection of either ISTH0036, relevant scrambled control oligonucleotide or saline was administered directly after laser procedure. Treatment outcome was studied by clinical investigation of the bleb in the GFS model every other day until day 28, whereas analysis of inflammation on day 5 (CD45) and angiogenesis on day 14 (FITC-dextran) was performed in the CNV model.

Results: In the GFS model, upon intracameral administration (and to a lesser extent, intravitreal injection), ISTH0036 was able to significantly increase bleb area, as compared to the control oligonucleotide and saline treated eyes. Analysis of bleb area showed that ISTH0036 significantly prolonged bleb survival. In the CNV model, intravitreal administration of ISTH0036 was able to significantly reduce the process of angiogenesis, as compared to saline- and control oligonucleotide-treated eyes. On day 5 after laser, no difference could be detected on the inflammatory process after ISTH0036 treatment versus saline or control oligonucleotide.

Conclusions: We have clearly demonstrated in both GFS and CNV murine models that ISTH0036, upon infrequent intra-ocular administrations, induces biological responses consistent with expected moleculat mechanism of action and long-lasting distribution in relevant eye tissues.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×